Curanex Pharmaceuticals (CURX) Cash from Operations (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Cash from Operations came in at 857404.0 in Q4 2025, down 798.49% YoY from 122750.72 in Q4 2024, and up 90.67% on a QoQ basis from 9187019.0 in Q3 2025.
Curanex Pharmaceuticals (CURX) Cash from Operations (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Cash from Operations data on file, last reported at 857404.0 in Q4 2025.
- Quarterly Cash from Operations fell 798.49% year-over-year to 857404.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 10269793.0 (changed N/A YoY) and the FY2025 annual result came in at 10484452.0, down 1787.14% from the prior year.
- Cash from Operations climbed to 857404.0 in Q4 2025, from 9187019.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 95427.0 in Q4 2024 to a low of 9187019.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | -857,404.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -857,404.00 |
| Dec 31, 2025 | -857,404.00 |
| Sep 30, 2025 | -9.19 Mn |
| Sep 30, 2025 | -9.19 Mn |
| Dec 31, 2024 | -95,427.00 |
| Dec 31, 2024 | -95,427.00 |
| Sep 30, 2024 | -129,943.00 |
| Sep 30, 2024 | -129,943.00 |